Ropidoxuridine

DB06485InvestigationalSmall molecule

Ropidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.

Mechanism: Pharmacologically active on Thymidine kinase
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Formula / weight: C₉H₁₁IN₂O₄ · 338.101 g/mol (avg)
Also known as: 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODOPYRIMIDIN-2(1H)-ONE · 2(1H)-PYRIMIDINONE, 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODO- · 5-iodo-2-pyrimidinone-2'-deoxyribose
Code names: IPD-R · NSC-726188

Resolves to

Compound

UNII3HX21A3SQFCAS93265-81-7ChEMBLCHEMBL2103821

Structure

InChIKeyXIJXHOVKJAXCGJ-XLPZGREQSA-NSMILESOC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C=NC1=O

Targets

Q9QNF7TK

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ropidoxuridine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account